Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth Oltenfreiter

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|November 16, 2006
Imaging probes targeting matrix metalloproteinasesChristophe Van de Wiele, Ruth Oltenfreiter
Nuclear Medicine and Biology|June 29, 2004
Synthesis and assessment of [11C]acetylhomotaurine as an imaging agent for the study of the pharmacodynamic properties of acamprosate by positron emission tomographyJan Courtyn, Bart Cornelissen, Ruth Oltenfreiter, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|April 1, 2005
Synthesis, radiosynthesis, in vitro and preliminary in vivo evaluation of biphenyl carboxylic and hydroxamic matrix metalloproteinase (MMP) inhibitors as potential tumor imaging agentsRuth Oltenfreiter, Ludovicus Staelens, Ulrik Hillaert, et al.
Nuclear Medicine and Biology|June 29, 2005
In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor markerBart Cornelissen, Ruth Oltenfreiter, Veerle Kersemans, et al.
Nuclear Medicine and Biology|April 20, 2004
New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agentsRuth Oltenfreiter, Ludovicus Staelens, Annabelle Lejeune, et al.
Nuclear Medicine Communications|January 20, 2005
Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factorBart Cornelissen, Veerle Kersemans, Ingrid Burvenich, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 27, 2002
Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imagingChristophe Van De Wiele, Ruth Oltenfreiter, Olivier De Winter, et al.
Nuclear Medicine and Biology|April 12, 2005
In vivo evaluation of [(123)I]-3-(4-iodobenzyl)-1,2,3,4-tetrahydro-8-hydroxychromeno[3,4-c]pyridin-5-one: a presumed dopamine D4 receptor ligand for SPECT studiesLudovicus Staelens, Ruth Oltenfreiter, Peter Blanckaert, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 28, 2011
Intra-arterial treatment with ⁹⁰Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University HospitalBieke Lambert, Emiel Sturm, Jeroen Mertens, et al.
Nuclear Medicine and Biology|February 22, 2005
In vivo evaluation of [123I]-4-iodo-N-(4-(4-(2-methoxyphenyl)-piperazin-1-yl)butyl)-benzamide: a potential sigma receptor ligand for SPECT studiesLudovicus Staelens, Ruth Oltenfreiter, Filip Dumont, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Cancer Biotherapy & Radiopharmaceuticals|November 16, 2006
Imaging probes targeting matrix metalloproteinasesChristophe Van de Wiele, Ruth Oltenfreiter
Nuclear Medicine and Biology|June 29, 2004
Synthesis and assessment of [11C]acetylhomotaurine as an imaging agent for the study of the pharmacodynamic properties of acamprosate by positron emission tomographyJan Courtyn, Bart Cornelissen, Ruth Oltenfreiter, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|April 1, 2005
Synthesis, radiosynthesis, in vitro and preliminary in vivo evaluation of biphenyl carboxylic and hydroxamic matrix metalloproteinase (MMP) inhibitors as potential tumor imaging agentsRuth Oltenfreiter, Ludovicus Staelens, Ulrik Hillaert, et al.
Nuclear Medicine and Biology|June 29, 2005
In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor markerBart Cornelissen, Ruth Oltenfreiter, Veerle Kersemans, et al.
Nuclear Medicine and Biology|April 20, 2004
New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agentsRuth Oltenfreiter, Ludovicus Staelens, Annabelle Lejeune, et al.
Nuclear Medicine Communications|January 20, 2005
Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factorBart Cornelissen, Veerle Kersemans, Ingrid Burvenich, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 27, 2002
Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imagingChristophe Van De Wiele, Ruth Oltenfreiter, Olivier De Winter, et al.
Nuclear Medicine and Biology|April 12, 2005
In vivo evaluation of [(123)I]-3-(4-iodobenzyl)-1,2,3,4-tetrahydro-8-hydroxychromeno[3,4-c]pyridin-5-one: a presumed dopamine D4 receptor ligand for SPECT studiesLudovicus Staelens, Ruth Oltenfreiter, Peter Blanckaert, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 28, 2011
Intra-arterial treatment with ⁹⁰Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University HospitalBieke Lambert, Emiel Sturm, Jeroen Mertens, et al.
Nuclear Medicine and Biology|February 22, 2005
In vivo evaluation of [123I]-4-iodo-N-(4-(4-(2-methoxyphenyl)-piperazin-1-yl)butyl)-benzamide: a potential sigma receptor ligand for SPECT studiesLudovicus Staelens, Ruth Oltenfreiter, Filip Dumont, et al.
Pageof 2